Pfizer | PFE - Ordinary Share Capital


Pfizer reported $5.7B in Ordinary Share Capital for its fiscal quarter ending in September of 2026.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 608K Jun/2026
Abbott USD 1.74B 2.94M Mar/2026
ALKERMES USD 168.03M 489K Sep/2026
Amgen USD 541M 0 Sep/2026
AstraZeneca USD 1.55B 28K Sep/2026
Bayer EUR 982.42M 0 Sep/2026
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 7M Jun/2026
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Drreddys Laboratories INR 833.07M 382K Sep/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
Glaxosmithkline GBP 2.02B 2.03B Sep/2026
J&J USD 2.41B 1.64M Jun/2026
Medtronic USD 1.28B 130K Jun/2026
Merck USD 2.47B 1.05M Jun/2026
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Novartis USD 1.89B 12.09M Sep/2026
Novartis USD 1.89B 19.47M Sep/2026
Pacira USD 39.9M 75K Sep/2026
Perrigo USD 138.8M 700K Sep/2026
Pfizer USD 5.7B 1000K Sep/2026
Phibro Animal Health USD 40.48M 0 Dec/2025
Prestige Brands USD 47.37M 53K Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.2B 0 Sep/2026
Sanofi EUR 1.2B 2.15M Jun/2026
Vertex Pharmaceuticals USD 253.5M 200K Sep/2026
Zoetis USD 407.49M 6.67M Sep/2026